hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06330064 id: DS7300-203 id: 2023-509632-26 type: OTHER domain: EU CTR briefTitle: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors overallStatus: RECRUITING date: 2024-04-10 date: 2026-12-01 date: 2028-07-01 date: 2024-03-26 date: 2024-04-16 name: Daiichi Sankyo class: INDUSTRY name: Merck Sharp & Dohme LLC briefSummary: This study is designed to assess the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); non-squamous non-small cell lung cancer (NSCLC); and urothelial carcinoma (UC). conditions: Recurrent or Metastatic Solid Tumors studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 260 type: ESTIMATED name: Ifinatamab deruxtecan measure: Objective Response Rate (ORR) as Assessed by Investigator measure: Number of Dose-limiting Toxicities in the HCC Cohort measure: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) measure: Duration of Response (DoR) measure: Progression-free Survival (PFS) measure: Disease Control Rate (DCR) measure: Overall Survival (OS) measure: Pharmacokinetic Parameter Maximum Concentration (CMax) for I DXd, total anti-B7-H3 antibody, and DXd measure: Pharmacokinetic Parameter Time to Reach Maximum Plasma Concentration (TMax) for I DXd, total anti-B7-H3 antibody, and DXd measure: Pharmacokinetic Parameter Half-life (t1/2) for I DXd, total anti-B7-H3 antibody, and DXd measure: Pharmacokinetic Parameter Minimum Concentration (Ctrough) for I DXd, total anti-B7-H3 antibody, and DXd measure: Pharmacokinetic Parameter Area Under the Curve (AUC) for I DXd, total anti-B7-H3 antibody, and DXd measure: Percentage of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) measure: Percentage of Participants Who Have Treatment-emergent ADA sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinical Research Alliance, Inc. status: RECRUITING city: Westbury state: New York zip: 11590 country: United States lat: 40.75566 lon: -73.58763 hasResults: False
nctId: NCT06330051 id: KY 2023-184-02 briefTitle: The Improve Acute Reperfusion Treatment Quality for Ischemic Stroke Through Spatiotemporal Computing in China acronym: IMPROVE-II overallStatus: NOT_YET_RECRUITING date: 2024-03-18 date: 2025-03-18 date: 2025-04-20 date: 2024-03-26 date: 2024-03-26 name: Beijing Tiantan Hospital class: OTHER briefSummary: This study intends to construct the goal-oriented integrated intervention model for AIS in-hospital procedure through the spatiotemporal positioning and the P-D-C-A cycle for continuous improvement (FAST model). Then a multicenter, evaluator-blind, cluster-randomized controlled study aims to verify the validity and safety of this FAST model. conditions: Acute Ischemic Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE maskingDescription: After 2 months of baseline information collection,10 hospitals will be seleted and then randomly assigned to the control and intervention groups according to hospital level and baseline DNT to reduce the imbalance between the two groups. We will not indicate to any hospital the grouping type of other hospitals. If the selected hospital is unable to complete the study for some reason during the operation, the hospital with conditions to carry out the replacement will be selected from the hospitals of the same region, the same level and the same scale. whoMasked: OUTCOMES_ASSESSOR count: 600 type: ESTIMATED name: improvement acute reperfusion treatment quality for stroke through spatiotemporal computing measure: The Door to Needle time (DNT) for intravenous thrombolytic therapy in eligible patients within 4.5 hours of onset. measure: The Door to Puncture time (DPT) for endovascular treatment within 6 hours of onset in eligible patients admitted to hospital within 4.5 hours of onset. measure: The rate of intravenous thrombolytic therapy in eligible patients within 4.5 hours of onset. measure: The rate of endovascular treatment within 6 hours of onset in eligible patients admitted to hospital within 4.5 hours of onset. measure: Incidence of symptomatic intracranial hemorrhage (sICH) within 36 hours of receiving reperfusion therapy. measure: Proportion of patients with 90-day favorable functional outcome. measure: Proportion of patients with 90-day independent functional outcome. measure: in-hospital mortality measure: 90-day mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330038 id: SMC 2024-01-065 briefTitle: Anesthesia and Non-small Cell Lung Cancer Recurrence acronym: GASTIVA overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-12-31 date: 2028-12-31 date: 2024-03-26 date: 2024-03-28 name: Samsung Medical Center class: OTHER name: Seoul National University Hospital name: Asan Medical Center name: Severance Hospital name: Seoul St. Mary's Hospital name: Korea University Guro Hospital name: DongGuk University name: Inha University Hospital name: Konkuk University Medical Center name: Ewha Womans University name: Chungnam National University Hospital name: University of Virginia name: Memorial Sloan Kettering Cancer Center name: Yale University name: Mayo Clinic name: University of Texas Southwestern Medical Center name: University Hospitals Coventry and Warwickshire NHS Trust name: Khon Kaen University name: King Chulalongkorn Memorial Hospital name: The Affiliated Hospital of Qingdao University name: Beijing Hospital name: All India Institute of Medical Sciences, New Delhi briefSummary: There has been ongoing debate about the relationship between cancer recurrence and anesthetic management. Therefore, the investigators will test the hypothesis that the recurrence free survival (RFS) after curative resection of NSCLC is higher in patient who received total intravenous anesthesia (TIVA) than volatile anesthetics in this multi-center randomized trials. conditions: Non-small Cell Lung Cancer conditions: Surgery conditions: Anesthesia studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 5384 type: ESTIMATED name: Propofol name: Inhaled anesthetics measure: Recurrence free survival measure: Overall survival measure: Postoperative complications sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330025 id: 69HCL23_1180 briefTitle: Exploring Food Rejection Dispositions as Potential Risk Factors for Undernutrition in Hospitalized Children Aged 2 to 8 acronym: MEDIALIME overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-05 date: 2025-05 date: 2024-03-26 date: 2024-03-26 name: Hospices Civils de Lyon class: OTHER briefSummary: Undernutrition affects over 30% of hospitalized children in France, with 10% severely malnourished yet only half of the cases are diagnosed. Undernutrition deteriorates children's health during hospital stays, weakening immunity and hindering recovery. Children suffering from acute malnutrition can stay in the hospital 45% longer than non-malnourished patients.
The MEDIC project aims to investigate if increased food rejection dispositions contribute to reduced food intake in hospitalized children. Food rejections are typically observed between 2 and 8 years. Some children are more challenging and eat only a few different foods, while others try everything. Around the age of 2, children become more selective about the foods they consume. This is largely due to two common dispositions in young children: food neophobia and food pickiness. Food neophobia is defined as the reluctance to eat or even try foods that appear new, whereas food pickiness is defined as the rejection of a substantial number of familiar foods, including foods previously tasted. Both pickiness and neophobia have been associated with a significant reduction in food consumption (especially of vegetables), a decrease in food variety, and less enjoyment derived from food. A study showed that children aged 2 to 5 were twice as likely to be underweight if they were picky eaters.
The MEDIC project seeks to assess health inequalities by studying the impact of food rejection dispositions on the nutritional status of children in pediatric services. A qualitative study supports the notion that food rejection is heightened during the hospitalization: half of the parents of hospitalized children interviewed reported that foods accepted outside the hospital were rejected in the ward. Parents indicated that their child's food preferences were more limited, and they only alternated between a few foods after entering the hospital. According to the majority of interviewed nurses, children refuse any food other than that provided by parents.
The research hypotheses of the MEDIC project focus on understanding the moderating effects of food rejection dispositions and socioeconomic backgrounds on children's food intake during hospitalization. Two hypotheses are formulated: (H1) the pre-hospitalization food rejection levels predict the amount of food consumed during the hospital stay, and (H2) children from disadvantaged socioeconomic backgrounds are more likely to refuse food during their hospital stay than those from more advantaged backgrounds. To test these hypotheses, parents of children aged 2 to 8 will complete questionnaires on food rejection dispositions upon admission, and food consumption (in grams and calories) will be assessed through weighing and photographs of meal trays taken 48 hours (± 24 hours) post-admission. The project aims to shed light on the complexities of childhood malnutrition, addressing social inequalities and contributing valuable insights for interventions and public health policy. conditions: Undernutrition studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 102 type: ESTIMATED name: Children between 2 and 8 years, without medical treatments or pathologies impacting food intake and his parents measure: Grams of hospital meals consumed by the patients at lunch measure: Calories of hospital meals consumed by the patients at lunch, 48 hours after their admission to the hospital. sex: ALL minimumAge: 2 Years maximumAge: 8 Years stdAges: CHILD facility: Hôpital Femme Mère Enfant de Lyon city: Bron zip: 69677 country: France name: Noël PERETTI, MD role: CONTACT phone: +33 (0)4.72.35.70.50 email: noel.peretti@chu-lyon.fr lat: 45.73333 lon: 4.91667 hasResults: False
nctId: NCT06330012 id: GeoMx_Breast briefTitle: The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients. overallStatus: RECRUITING date: 2024-03-18 date: 2025-01-15 date: 2027-12-31 date: 2024-03-26 date: 2024-03-26 name: Samsung Medical Center class: OTHER briefSummary: This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients. conditions: HER2-positive Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 50 type: ESTIMATED name: GeoMx data analysis with clinical outcome measure: Spatial transcriptomic analysis sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Ji-Yeon Kim status: RECRUITING city: Seoul zip: 06351 country: Korea, Republic of name: Ji-Yeon Kim role: CONTACT phone: 82-2-3410-3459 email: jyeon25@skku.edu name: MIRYOUNG HONG role: CONTACT phone: 82-2-2148-7147 email: ring7629@naver.com lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06329999 id: CMG-sAML-001 briefTitle: A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML overallStatus: RECRUITING date: 2024-02-03 date: 2025-12-31 date: 2027-12-31 date: 2024-03-26 date: 2024-03-26 name: Ruijin Hospital class: OTHER name: Huadong Hospital name: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine name: Huashan Hospital name: Army Medical Center of PLA name: Sun Yat-sen University name: RenJi Hospital name: Shanghai Jiading District Central Hospital name: The Second Affiliated Hospital of Dalian Medical University name: First Hospital of China Medical University name: Dalian Municipal Central Hospital name: Shanghai Zhongshan Hospital name: Shanghai Pudong Hospital name: Shanghai Public Health Clinical Center name: Xuhui Central Hospital, Shanghai name: The Affiliated People's Hospital of Ningbo University name: Taizhou First People's Hospital name: Wenzhou People's Hospital briefSummary: The goal of this clinical trial\] is to evaluate mitoxantrone hydrochloride liposomes, subcutaneous injection of cytarabine and G-CSF combined with Venetoclax (CMG+Ven) in adult secondary acute myeloid leukemia and myelodysplastic syndrome with increased primordial cells type 2(MDS-IB2) or elderly acute myeloid leukemia\]. The main questions it aims to answer are:
* Evaluation of the safety conditions: Recurrent Adult Acute Myeloid Leukemia conditions: Myelodysplastic Syndrome conditions: Adult Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 78 type: ESTIMATED name: CMGV measure: CRc measure: ORR measure: OS measure: RFS measure: MRD- measure: Adverse Event sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ruijin Hospital status: RECRUITING city: Shanghai state: Shanghai country: China name: xiaoqian Xu, Doctor role: CONTACT phone: 13816205940 email: Ellenxxq@qq.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06329986 id: SEDPTC20240109 briefTitle: Crossover RCT of TAMER Lenses in Myopia Control overallStatus: RECRUITING date: 2024-02-24 date: 2025-06 date: 2026-01 date: 2024-03-26 date: 2024-03-26 name: Shanghai Eye Disease Prevention and Treatment Center class: OTHER briefSummary: This study is a prospective, randomized, crossover clinical trial with a planned proposed enrollment of 120 Chinese male and female subjects aged 6-12 years without systemic or ocular diseases to follow up their cycloplegic equivalent spherical lens power and other relevant indices in order to determine the role of TAMER lenses in myopia control as compared to singlie vision lenses. conditions: Myopia conditions: Progressive studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: TAMER Lens Spectacle name: SV lenses measure: Spherical Equivalent change measure: Axial Length change measure: Spherical Equivalent change sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Shanghai Eye Disease Prevention and Treatment Center status: RECRUITING city: Shanghai state: Shanghai zip: 200041 country: China name: Xiangui He role: CONTACT phone: 021-62982727-817 lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06329973 id: 2023-237 briefTitle: Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer overallStatus: RECRUITING date: 2024-02-28 date: 2025-12-15 date: 2028-02-15 date: 2024-03-26 date: 2024-03-26 name: Henan Cancer Hospital class: OTHER_GOV briefSummary: Based on the current status and progress in the treatment of gastric cancer, our center prospectively designed a first-line comprehensive treatment plan for unresectable or postoperative recurrent advanced gastric/gastroesophageal conjoint adenocarcinoma, fruquintinib + sintilimab + oxaliplatin + Capecitabine (CAPEOX), which utilizes the tumor immunomodulation and vascular normalization effects of fruquintinib. While improving the effective perfusion of intravenous chemotherapy with CAPEOX regimen, further combining with PD-1 monoclonal antibody to regulate the immunosuppressive microenvironment and reactivate the anti-tumor immune response of the body. An exploratory dose-climbing trial was designed to evaluate the clinical efficacy and safety of fruquintinib in combination with Sintilimab and CAPEOX in clinical practice. At the same time, changes in genome, pathology and immune microenvironment of tumor-related tissues before and after treatment were observed, and molecular markers related to curative effect were screened to explore the molecular mechanism affecting the curative effect of combination therapy, and further enrichment of therapeutic advantage groups to improve the surgical conversion rate laid the foundation for future large-scale clinical studies conditions: Metastatic Gastroesophageal Junction Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 70 type: ESTIMATED name: Fruquintinib in combination with Sintilimab and CAPEOX measure: Objective response rate measure: Maximum tolerated dose measure: Overall Survival measure: Progression Free Survival measure: Disease Control Rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Henan Cancer Hospital status: RECRUITING city: Zhengzhou state: Henan zip: 450008 country: China name: Xiaobing Chen role: CONTACT phone: +8613937100233 lat: 34.75778 lon: 113.64861 hasResults: False
nctId: NCT06329960 id: 2024PHB019-001(3) briefTitle: Dorsal Scapular Nerve Injection Combined With Muscle Needle Release overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-05-30 date: 2024-11-30 date: 2024-03-26 date: 2024-04-16 name: Peking University People's Hospital class: OTHER briefSummary: Ultrasound-guided perineural injection (PIT) of 5% dextrose (D5W) hydrodissection has been widely used in the treatment of peripheral entrapment neuropathies. However, there are few studies investigating the efficacy of PIT using D5W HD for dorsal scapular nerve (DSN) entrapment. Generally, the DSN entrapment causes the stiffness of the major and minor rhomboideus(2). In clinical practice, the investigators observed that ultrasound-guided PIT using D5W HD combined with needle release of major and minor rhomboideus significantly relieved the pain of scapular region. Therefore, the investigators aimed to evaluate the 6-month efficacy of this procedure for the participants with DSN entrapment. conditions: Dorsal Scapular Nerve Entrapment studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Ultrasound-guided injection combined with needle release measure: visual analogue scale (VAS) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jiaan Zhu city: Beijing country: China name: Jiaan Zhu role: CONTACT email: canzhujia@126.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06329947 id: HMPL-012-SPRING-P106 briefTitle: A Phase II Study of Surufatinib Combined With PD-L1 and mFOLFOX6 as Second-line Treatment for Advanced PRAD overallStatus: NOT_YET_RECRUITING date: 2024-03-22 date: 2025-01-01 date: 2026-09-30 date: 2024-03-26 date: 2024-03-26 name: Rui-hua Xu, MD, PhD class: OTHER briefSummary: To preliminarily evaluate whether there is a survival benefit of surufatinib in combination with Caralizumab and mFOLFOX6 in the second-line treatment of advanced pancreatic cancer, and to explore the feasibility of second-line and post-line treatment for advanced pancreatic cancer conditions: Advanced Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 37 type: ESTIMATED name: Surufatinib in combination with Caralizumab and mFOLFOX6 measure: objective response rate (ORR) measure: disease control rate (DCR) measure: Progression-Free Survival (PFS) measure: overall survival (OS) measure: quality of life (QoL) measure: adverse events (AE) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SunYat-senUniversity Cancer Center city: Guangzhou country: China lat: 23.11667 lon: 113.25 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-12-12 uploadDate: 2024-03-18T20:39 filename: Prot_000.pdf size: 1380851 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-12-12 uploadDate: 2024-03-18T20:39 filename: ICF_001.pdf size: 541718 hasResults: False
nctId: NCT06329934 id: XXZY-003 briefTitle: Refined Nursing in Rehabilitation Training overallStatus: COMPLETED date: 2022-05-01 date: 2023-05-31 date: 2024-01-01 date: 2024-03-26 date: 2024-03-26 name: Xinxiang Central Hospital class: OTHER briefSummary: This study is to explore the clinical effect of refined nursing in rehabilitation training for patients with brain injury during the recovery period. Patients in the control group were provided with routine nursing intervention, while patients in the study group adopted a nursing mode based on the concept of refinement treatment. Comparison was made in terms of the Glasgow Coma Scale (GCS) score, cognitive function score, functional independence score, nursing satisfaction, and incidence of complications. conditions: Brain Injuries studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 96 type: ACTUAL name: Establishment of a hierarchical monitoring and management team name: Assessment of pressure injury name: Communication name: Intervention for pressure ulcer name: Rehabilitation training name: introduction of the current patient's condition to family members name: maintaining appropriate temperature and humidity in the ward name: careful observation of vital signs in patients measure: GCS scores measure: GCS scores measure: cognitive function scores measure: cognitive function scores measure: functional independence scores measure: functional independence scores measure: Newcastle Satisfaction with Nursing Scale (NSNS) measure: Newcastle Satisfaction with Nursing Scale (NSNS) measure: incidence of adverse reactions measure: incidence of adverse reactions sex: ALL minimumAge: 33 Years maximumAge: 43 Years stdAges: ADULT facility: Effect of Refined Nursing in Rehabilitation Training for Patients with Brain Injury During the Recovery Period: An Observational Study city: Xinxiang state: Henan zip: 453000 country: China lat: 35.19033 lon: 113.80151 hasResults: False